AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Koselugo (selumetinib) by Year
Koselugo (selumetinib) — Emerging Markets product sales ($M) ($M)
AstraZeneca Koselugo (selumetinib): $228M in FY2025, up 28.8% from a year earlier.
Latest, FY2025
228
Period ended Dec 31, 2025
Change on a year earlier
+28.8%
177 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Koselugo | 662 | 25 | 22 | 219 | 3 | 228 | 29 | 25 | 161 | 57 | 51 | 54 | 38 | 38”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Koselugo (selumetinib) — Emerging Markets product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 228 | +28.8% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 177 | +200.0% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 59 | +126.9% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 26 | +2,500.0% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up koselugo (selumetinib)
Cite this data
StockData. (2026). AstraZeneca Koselugo (selumetinib) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-koselugo-em
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.